TRANSLEISH

TRANSLEISH synergizes important national expertise of its academic partners at Institut Pasteur and CNRS, and its industrial partner ManRos Therapeutics in Leishmania signal transduction and kinase-biased drug development. It builds on important intellectual property generated through the EU-sponsored LEISHDRUG consortium, including innovative activity-based target screens, phenotypic drug screening assays, and hit compound identification using a unique kinase-biased compound library. The major aim of TRANSLEISH is to translate these important resources into pre-clinical application and to coordinate the first essential steps towards the development of novel anti-parasitic drug leads ... The protozoan parasite Leishmania donovani causes fatal human visceral leishmaniasis , one of the most neglected tropical diseases. In the absence of economic incentive, serious Research and Development (R&D) investments into anti-leishmanial drug development lack from the portfolio of the major..